Exposure to Green Space Boosts Young Children's Bone Mineral Density
By Lori Solomon HealthDay Reporter
TUESDAY, Jan. 9, 2024 -- For children in early childhood, exposure to green space has a positive impact on bone health, according to a study published online Jan. 4 in JAMA Network Open.
Hanne Sleurs, from Hasselt University in Belgium, and colleagues investigated whether early-life exposure to residential surrounding green space is associated with a change in bone mineral density in young children. The analysis included mother-child pairs who were recruited at birth and followed for four to six years (327 children).
The researchers found that early-life exposure to residential green space was associated with increased childhood bone health. There was an association observed between an interquartile range (IQR) increase in total green (21.2 percent) and high green (19.9 percent) space within 500 m of the residence and an increase of 27.38 m/second and 25.30 m/second in bone mineral density, respectively. An IQR increase in total (25.2 percent) and high (23.2 percent) green space within 1,000 m of a residence was associated with a lower risk for having a bone density lower than the sex-specific 10th percentile (3,567.6 m/second for girls and 3,522.8 m/second for boys).
"These findings highlight the importance of early-life exposure to residential green space on bone health during critical periods of growth and development, with long-term implications," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-10 02:15
Read more
- Bird Flu Infection Confirmed in a Pig for First Time in U.S.
- America's Epidemic of STDs May Finally Be Slowing
- Female Pediatricians Earn About 93 Percent of Male Pediatricians
- CDC Says Some People May Need Extra Dose of COVID Vaccine
- COVID Vaccine Mistrust Levels Aren't Budging, Study Finds
- Avadel Pharmaceuticals Announces FDA Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions